TABLE 1.
Susceptibilities of HIV-1 with INSTI and/or NRTI drug resistance mutations to antiretroviral drugs
| Virus mutant | Fold change in EC50 relative to wild typea |
|||||||
|---|---|---|---|---|---|---|---|---|
| INSTIs |
NRTIs |
PI |
NNRTI |
|||||
| EVG | RAL | DTG | TFV | FTC | AZT | DRV | EFV | |
| IN-E92Q | 50 | 11 | 2.0 | 1.2 | 1.3 | 0.7 | 0.9 | 0.8 |
| RT-M184V + IN-E92Q | 41 | 9.3 | 1.7 | 0.7 | >1,000 | 0.3 | 0.8 | 0.5 |
| RT-K65R/M184V + IN-E92Q | 55 | 12 | 2.0 | 2.6 | >1,000 | 0.3 | 0.9 | 0.6 |
| RT-M184V | 1.0 | 1.0 | 1.1 | 0.7 | >1,000 | 0.4 | 0.9 | 0.8 |
| RT-K65R | 1.4 | 1.1 | 1.2 | 4.1 | 20 | 0.5 | 1.1 | 0.7 |
| RT-K65R/M184V | 1.3 | 1.1 | 1.1 | 2.6 | >1,000 | 0.3 | 0.9 | 0.4 |
a
The data shown represent the means from at least 3 independent experiments. The EC50s for the wild type were 2.3 nM for EVG, 6.6 nM for RAL, 0.8 nM for DTG, 4.1 μM for TFV, 0.7 μM for FTC, 0.2 μM for AZT, 6.6 nM for DRV, and 1.3 nM for EFV. Fold changes were calculated by setting the wild-type EC50 at 1, and all fold change values of >2.5 (in boldface) demonstrated a statistically significant difference using a two-tailed Student's t test (P < 0.05).